CD105 (endoglin) as risk marker in AML patients undergoing stem cell transplantation

• Published in: International journal of hematology Vol. 112; no. 1; pp. 57 - 64
• Main Authors: Märklin, Melanie, Hagelstein, Ilona, Hinterleitner, Clemens, Salih, Helmut R., Kauer, Joseph, Heitmann, Jonas S.
• Format: Journal Article
• Language: English
• Published: Singapore Springer Singapore 01-07-2020; Springer Nature B.V
• Subjects: Acute myeloid leukemia; Bone marrow; Bone tumors; CD105 antigen; Classification; Endoglin; Endothelial cells; Flow cytometry; Hematology; Hematopoietic stem cells; Leukemia; Markers; Medical prognosis; Medicine; Medicine & Public Health; Myeloid leukemia; Oncology; Original Article; Repopulation; Solid tumors; Stem cell transplantation; Stem cells; Survival; Transplantation; Transplants & implants; Tumors; Endoglin; CD105; Allogeneic transplantation; Acute myeloid leukemia; Risk assessment
• ISSN: 0925-5710; 1865-3774
• DOI: 10.1007/s12185-020-02875-0

Several genetic and molecular markers are general predictors of outcome in acute myeloid leukemia (AML), but only few are predictive of outcomes after allogeneic hematopoietic stem cell transplantation (HSCT). Novel markers are needed to improve treatment decisions regarding HSCT. CD105 (endoglin) is a type I transmembrane protein capable of activating endothelial cells. Moreover, CD105 mediates stem cell properties of hematopoietic stem cells and enables repopulation within the bone marrow. Expression of CD105 on vessels of solid tumors and on AML blasts is correlated with poor prognosis. We recently demonstrated that CD105 expression is an independent predictor of overall survival in AML. However, its role in patients receiving intensive treatment with consecutive allogenic transplantation has not been assessed. Using flow cytometry, we analyzed primary samples of 41 patients who underwent HSCT. Using the previously defined SFI cut-off of 5.2, we identified differences in CD105 expression regarding FAB classification and NCCN risk score. Moreover, we detected differences regarding transplant indication and WHO classification with regards to CD105 surface levels. In patients undergoing HSCT high CD105 expression correlated significantly with poor overall survival. We identify CD105 expression in AML as prognostic marker for outcome after HSCT in AML.